A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation.

Karine RobitailleMarie-Hélène GuertinAfshin JamshidiHui Wen XuHélène HovingtonJean-François PelletierLisanne BeaudoinNikunj GevariyaLouis LacombeRabi TiguertYves CaumartinThierry DujardinPaul TorenMichele LoddeÉtienne RacineDominique TrudelMartine PerignyThierry DuchesneJosée SavardPierre JulienYves FradetVincent Fradet

Published in: Communications medicine (2024)

This MAG-EPA intervention did not affect the primary outcome of prostate cancer proliferation according to nuclear Ki-67 expression. More studies are needed to decipher the effects of long-chain omega-3 fatty acid dietary supplementation in men with prostate cancer.

Keyphrases

prostate cancer
fatty acid
radical prostatectomy
double blind
signaling pathway
randomized controlled trial
poor prognosis
open label
clinical trial
long non coding rna
middle aged
phase iii
rectal cancer
locally advanced